Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma
NCT07236528
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Mucosal Melanoma
Interventions
DRUG:
Carilizumab and Apatinib
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School